Molecular Pharmacology Program

The Michael Kharas Lab

Research

Pictured: Michael Kharas
Michael G. Kharas, PhD

The Kharas lab is working to identify critical pathways in both normal and leukemic hematopoietic cells.

View Lab Overview

Publications Highlights

Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells Park SM, Miyamoto DK, Han GYQ, Chan M, Curnutt NM, Tran NL, Velleca A, Kim JH, Schurer A, Chang K, Xu W, Kharas MG, Woo CM.  Cancer Cell. 2023 Apr 10;41(4):726-739.e11. doi: 10.1016/j.ccell.2023.02.010. Epub 2023 Mar 9. PMID: 36898380.

Serine synthesis pathway flux is essential for acute myeloid leukemia cells to proliferate in fructose-rich conditions.  Jeong S, Savino AM, Chirayil R, Cheng Y, Barin E, Park SM, Schurer A, Mullarky E, Cantley LC, Kharas MG*, Keshari KR*.  Cell Metab. 5 January 2021, Pages 145-159.

TP53 mutations and RNA binding protein MUSASHI2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.  Erazo T, Evans CM, Zakheim D, Chu KL, Refermat AY, Asgari Z, Yang Z, Ferreira MD, Mehta S, Russo MV, Knezevic A, Zhang XP, Chen Z, Fennell M, Garippa R, Seshan V, de Stanchina E, Barbash O, Batlevi CL, Melnick AM, Younes A*, Kharas MG*. Nat Comm 2022 September 27. 13(5626).

N6-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation Cheng Y*, Xie W*, Pickering BF, Chu KL, Savino AM, Yang X, Luo H, Nguyen DTT, Mo S, Barin E, Velleca A, Rohwetter T, Patel DJ, Jaffrey SR, Kharas MG*.  Cancer Cell. July 2021.

Transcriptional control of CBX5 by the RNA binding proteins RBMX/L1 maintain chromatin state in myeloid leukemia. Prieto C, Nguyen DTT, Liu Z,Wheat J, Perez A, Gourkanti S, Chou T, Barin E, Velleca A, Rohwetter T, Barin E, Chow A, Taggart J, Hoskova K, Dhodapkar M, Schurer A, Barlowe TS, Vu LP, Leslie C, Steidl U, Rabadan R, Kharas MG*.  Nat Cancer. July 2021. 5: 741-757.

View All Publications

People

Pictured: Michael Kharas

Michael G. Kharas, PhD

  • Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.
  • PhD, University of California Irvine
[email protected]
Email Address

Members

Emily Batchelor

Research Technician

Kathryn Chang

Research Technician

Chiara Evans
Chiara Evans

WCMC Graduate Student

Takeshi Irie
Takeshi Irie

Assistant Attending, Anesthesiology and Critical Care

Michael Kharas, PhD
Michael Kharas

Member

Hanzhi Luo
Hanzhi Luo

Research Fellow

Sibasish Mohanty

Research Scholar

Sun Mi Park
Sun Mi Park

Research Associate

Aspen Pierson

Research Technician

GSK Student
Isaac Wakiro

GSK Student

Wei Wei

Fellow, Graduate Medical Education

Laura Wilson
Laura Wilson

Senior SKI Administrative Assistant

Xueqin Xie
Xueqin Xie

Research Scholar - NYSTEM Training Award at the CSCB

Xuejing Yang
Xuejing Yang

Postdoctoral Fellow

Lab Alumni
Cynthia Almonte
Cynthia Almonte

Administrative Assistant

Elianna Amin

Research Fellow

Tatiana Erazo Andrade
Tatiana Erazo Andrade

Research Scholar

Ersilia Barin
Ersilia Barin

Graduate Student at Weill Cornell

Trevor Barlowe

Research Technician

Mandy Chan

Research Technician

Aaron Chang

Graduate Student

Yuanming  Cheng
Yuanming Cheng

Research Scholars

Timothy Chou
Timothy Chou

Research Technician

Arthur Chow
Arthur Chow

Research Technician

Karen Chu
Karen Chu
Pooja Desai

Lab Intern

Gerard Minuesa  Dinares , PhD
Gerard Minuesa Dinares

Biotech

Kim Do
Kim Do

Technician, Ly Vu Lab, BC Cancer Agency

Saroj Gourkanti
Saroj Gourkanti

Graduate Student at University of California, San Diego

Grace Han

Research Technician

Florisela Herrejon Chavez
Florisela Herrejon Chavez

Research Fellow, Earle A. Chiles Research Institute, Portland, OR

Tzu-Chieh Kate Ho
Tzu-Chieh Kate Ho

Research Scholar

Ming Jiang

Graduate Student

Diu Nguyen
Diu Nguyen

Research Scholars

Rachel Okabe

Lab Intern

Camila Prieto
Camila Prieto

Graduate Student

Thomas Rohwetter
Thomas Rohwetter
Angela Savino
Angela Savino
Alex Schurer
Alex Schurer

Medical Student at Albert Einstein

James Taggart

Research Technician

Patrick Tivnan
Patrick Tivnan

Research Technician

Anthony Velleca
Anthony Velleca
Ly Vu
Ly Vu

Assistant Professor, Simon Fraser University, Vancouver, BC, Canada

Lab Affiliations

Achievements

  • Leukemia and Lymphoma Society Career Development Award (2017)
  • Alex Lemonade Stand Foundation ‘A’ Award (2016)
  • American Society of Hematology Junior Faculty Scholar Award (2011)
  • Kimmel Scholar Award (2013)
  • V-Scholar Award (2013)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Research Technician

As a Research Technician you will perform research activities in collaboration with internal/external personnel to complete science-based projects. You will normally receive detailed instructions while making observations, analyzing data and interpreting results according to laboratory procedures. The Research Technician will provide support to all technical/research staff and postdocs.

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael G. Kharas discloses the following relationships and financial interests:

  • 858 Therapeutics, Inc.
    Equity; Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • Kumquat Biosciences
    Professional Services and Activities
  • Transition Bio, Inc.
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures